Clearmind Total Liab vs Net Debt Analysis

CMND Stock

USD 1.33 0.01 0.75%

Clearmind Medicine financial indicator trend analysis is way more than just evaluating Clearmind Medicine Common prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Clearmind Medicine Common is a good investment. Please check the relationship between Clearmind Medicine Total Liab and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Total Liab vs Net Debt

Total Liab vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Clearmind Medicine Common Total Liab account and Net Debt. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Clearmind Medicine's Total Liab and Net Debt is -0.69. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Net Debt in the same time period over historical financial statements of Clearmind Medicine Common, assuming nothing else is changed. The correlation between historical values of Clearmind Medicine's Total Liab and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Clearmind Medicine Common are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Total Liab i.e., Clearmind Medicine's Total Liab and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.69

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Clearmind Medicine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Clearmind Medicine Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At present, Clearmind Medicine's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 414.2 K, whereas Enterprise Value Over EBITDA is forecasted to decline to 0.40.

Clearmind Medicine fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Current Assets	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Other Current Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Non Current Liabilities Total	Common Stock Shares Outstanding	Other Stockholder Equity	Property Plant Equipment	Net Invested Capital	Capital Stock	Net Working Capital
Total Assets		0.79	0.77	-0.04	-0.77	0.6	0.99	0.72	0.79	0.32	1.0	0.32	0.92	0.79	-0.35	-0.98	0.36	1.0	0.93	0.04	0.84	0.87	-0.73	0.62	0.91	0.61
Total Current Liabilities	0.79		0.22	-0.62	-0.95	0.81	0.76	0.35	1.0	0.28	0.78	0.3	0.96	0.99	-0.35	-0.69	0.45	0.78	0.94	0.24	0.95	0.77	-0.55	0.02	0.97	0.0
Total Stockholder Equity	0.77	0.22		0.57	-0.22	0.07	0.8	0.74	0.22	0.21	0.78	0.19	0.46	0.23	-0.21	-0.85	0.05	0.78	0.5	-0.26	0.37	0.55	-0.57	0.97	0.44	0.97
Net Tangible Assets	-0.04	-0.62	0.57		0.51	-0.42	-0.02	0.46	-0.62	-0.02	-0.04	-0.07	-0.37	-0.65	0.13	-0.09	-0.11	-0.04	-0.32	-0.13	-0.55	-0.09	-0.08	0.73	-0.44	0.72
Retained Earnings	-0.77	-0.95	-0.22	0.51		-0.93	-0.72	-0.51	-0.95	-0.34	-0.75	-0.32	-0.95	-0.9	0.29	0.68	-0.64	-0.74	-0.94	-0.48	-0.83	-0.88	0.65	-0.05	-0.92	-0.01
Accounts Payable	0.6	0.81	0.07	-0.42	-0.93		0.52	0.58	0.81	0.3	0.56	0.28	0.82	0.72	-0.22	-0.48	0.82	0.55	0.83	0.76	0.6	0.83	-0.61	-0.06	0.76	-0.11
Cash	0.99	0.76	0.8	-0.02	-0.72	0.52		0.68	0.76	0.29	1.0	0.3	0.89	0.77	-0.38	-0.98	0.26	1.0	0.9	-0.07	0.84	0.82	-0.69	0.65	0.89	0.64
Other Current Assets	0.72	0.35	0.74	0.46	-0.51	0.58	0.68		0.35	0.26	0.7	0.21	0.6	0.27	-0.24	-0.73	0.58	0.68	0.64	0.44	0.28	0.8	-0.69	0.72	0.5	0.68
Total Liab	0.79	1.0	0.22	-0.62	-0.95	0.81	0.76	0.35		0.28	0.78	0.3	0.96	0.99	-0.35	-0.69	0.45	0.78	0.94	0.24	0.95	0.77	-0.55	0.02	0.97	0.0
Short Long Term Debt	0.32	0.28	0.21	-0.02	-0.34	0.3	0.29	0.26	0.28		0.3	0.97	0.33	0.25	0.27	-0.3	0.37	0.29	0.33	0.17	0.24	0.43	-0.42	0.16	0.3	0.15
Total Current Assets	1.0	0.78	0.78	-0.04	-0.75	0.56	1.0	0.7	0.78	0.3		0.31	0.91	0.78	-0.39	-0.98	0.3	1.0	0.92	-0.02	0.84	0.84	-0.7	0.63	0.91	0.62
Short Term Debt	0.32	0.3	0.19	-0.07	-0.32	0.28	0.3	0.21	0.3	0.97	0.31		0.33	0.28	0.16	-0.29	0.29	0.3	0.33	0.11	0.28	0.37	-0.35	0.13	0.32	0.12
Common Stock	0.92	0.96	0.46	-0.37	-0.95	0.82	0.89	0.6	0.96	0.33	0.91	0.33		0.93	-0.35	-0.84	0.53	0.9	1.0	0.27	0.92	0.9	-0.7	0.28	0.99	0.26
Other Current Liab	0.79	0.99	0.23	-0.65	-0.9	0.72	0.77	0.27	0.99	0.25	0.78	0.28	0.93		-0.37	-0.69	0.34	0.78	0.91	0.11	0.98	0.71	-0.49	0.02	0.97	0.01
Property Plant And Equipment Net	-0.35	-0.35	-0.21	0.13	0.29	-0.22	-0.38	-0.24	-0.35	0.27	-0.39	0.16	-0.35	-0.37		0.39	0.31	-0.4	-0.36	0.06	-0.37	-0.3	-0.03	-0.18	-0.38	-0.18
Net Debt	-0.98	-0.69	-0.85	-0.09	0.68	-0.48	-0.98	-0.73	-0.69	-0.3	-0.98	-0.29	-0.84	-0.69	0.39		-0.24	-0.98	-0.86	0.06	-0.77	-0.83	0.7	-0.73	-0.83	-0.72
Non Current Assets Total	0.36	0.45	0.05	-0.11	-0.64	0.82	0.26	0.58	0.45	0.37	0.3	0.29	0.53	0.34	0.31	-0.24		0.28	0.54	0.84	0.22	0.62	-0.61	-0.03	0.42	-0.09
Cash And Short Term Investments	1.0	0.78	0.78	-0.04	-0.74	0.55	1.0	0.68	0.78	0.29	1.0	0.3	0.9	0.78	-0.4	-0.98	0.28		0.91	-0.04	0.85	0.83	-0.69	0.64	0.9	0.63
Net Receivables	0.93	0.94	0.5	-0.32	-0.94	0.83	0.9	0.64	0.94	0.33	0.92	0.33	1.0	0.91	-0.36	-0.86	0.54	0.91		0.29	0.9	0.91	-0.7	0.32	0.98	0.29
Non Current Liabilities Total	0.04	0.24	-0.26	-0.13	-0.48	0.76	-0.07	0.44	0.24	0.17	-0.02	0.11	0.27	0.11	0.06	0.06	0.84	-0.04	0.29		-0.06	0.45	-0.33	-0.26	0.15	-0.33
Common Stock Shares Outstanding	0.84	0.95	0.37	-0.55	-0.83	0.6	0.84	0.28	0.95	0.24	0.84	0.28	0.92	0.98	-0.37	-0.77	0.22	0.85	0.9	-0.06		0.68	-0.5	0.16	0.96	0.16
Other Stockholder Equity	0.87	0.77	0.55	-0.09	-0.88	0.83	0.82	0.8	0.77	0.43	0.84	0.37	0.9	0.71	-0.3	-0.83	0.62	0.83	0.91	0.45	0.68		-0.8	0.43	0.84	0.4
Property Plant Equipment	-0.73	-0.55	-0.57	-0.08	0.65	-0.61	-0.69	-0.69	-0.55	-0.42	-0.7	-0.35	-0.7	-0.49	-0.03	0.7	-0.61	-0.69	-0.7	-0.33	-0.5	-0.8		-0.49	-0.64	-0.45
Net Invested Capital	0.62	0.02	0.97	0.73	-0.05	-0.06	0.65	0.72	0.02	0.16	0.63	0.13	0.28	0.02	-0.18	-0.73	-0.03	0.64	0.32	-0.26	0.16	0.43	-0.49		0.25	1.0
Capital Stock	0.91	0.97	0.44	-0.44	-0.92	0.76	0.89	0.5	0.97	0.3	0.91	0.32	0.99	0.97	-0.38	-0.83	0.42	0.9	0.98	0.15	0.96	0.84	-0.64	0.25		0.23
Net Working Capital	0.61	0.0	0.97	0.72	-0.01	-0.11	0.64	0.68	0.0	0.15	0.62	0.12	0.26	0.01	-0.18	-0.72	-0.09	0.63	0.29	-0.33	0.16	0.4	-0.45	1.0	0.23

Click cells to compare fundamentals

Clearmind Medicine Account Relationship Matchups

Clearmind Medicine fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	512.7K	5.2M	1.1M	4.3M	5.0M	5.2M
Total Current Liabilities	13.4K	357.2K	2.6M	3.6M	4.2M	4.4M
Total Stockholder Equity	499.3K	4.8M	(1.5M)	1.4M	1.6M	1.6M
Net Tangible Assets	133.8K	319.6K	4.6M	(1.7M)	(1.9M)	(1.8M)
Retained Earnings	(539.7K)	(4.4M)	(13.8M)	(13.6M)	(12.3M)	(11.7M)
Accounts Payable	4.0K	281.5K	1.0M	448.2K	515.4K	541.2K
Cash	329.8K	4.6M	175.8K	3.9M	4.5M	4.7M
Total Liab	13.4K	357.2K	2.6M	3.6M	4.2M	4.4M
Total Current Assets	333.0K	4.9M	593.3K	4.2M	4.8M	5.1M
Common Stock	891.7K	7.9M	9.2M	12.4M	14.3M	15.0M
Other Current Liab	6.1K	6.7K	1.6M	3.2M	3.6M	3.8M
Property Plant And Equipment Net	179.7K	20.6K	66.4K	1.2K	1.1K	1.1K
Net Debt	(329.8K)	(4.6M)	(123.4K)	(3.9M)	(3.5M)	(3.4M)
Non Current Assets Total	179.7K	238.6K	534.7K	115.3K	132.6K	224.1K
Cash And Short Term Investments	329.8K	4.6M	440.2K	4.0M	4.6M	4.8M
Net Receivables	3.1K	129.8K	133.7K	174.6K	200.8K	210.8K
Liabilities And Stockholders Equity	512.7K	5.2M	1.1M	4.3M	5.0M	5.2M
Non Current Liabilities Total	7.6K	12.7K	5.3K	348.9K	2.0M	0.0
Common Stock Shares Outstanding	18.1K	30.9K	43.3K	202.5K	232.9K	244.5K
Other Stockholder Equity	369.7K	2.9M	2.5M	2.6M	3.0M	1.6M
Net Invested Capital	499.3K	4.8M	(1.5M)	983.5K	885.1K	785.4K
Capital Stock	891.7K	7.9M	9.2M	17.1M	19.7M	20.7M
Net Working Capital	319.6K	4.6M	(2.0M)	824.8K	742.3K	579.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Clearmind Medicine Common is a strong investment it is important to analyze Clearmind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearmind Medicine's future performance. For an informed investment choice regarding Clearmind Stock, refer to the following important reports:

How To Invest In Clearmind

Details

Is Clearmind Stock a good investment?

Details

What is Clearmind Medicine's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearmind Medicine. If investors know Clearmind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearmind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.23)

Return On Assets

(0.58)

Return On Equity

(2.68)

The market value of Clearmind Medicine Common is measured differently than its book value, which is the value of Clearmind that is recorded on the company's balance sheet. Investors also form their own opinion of Clearmind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Clearmind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearmind Medicine's market value can be influenced by many factors that don't directly affect Clearmind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Clearmind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearmind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearmind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Clearmind Total Liab vs Net Debt Analysis

Total Liab vs Net Debt

Total Liab vs Net Debt Correlation Analysis

Correlation Coefficient

Total Liab

Net Debt

Clearmind Medicine fundamental ratios Correlations

Clearmind Medicine Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Clearmind Medicine fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash
Cash And Short Term Investments	+ 1.0	Cash
Cash And Short Term Investments	+ 1.0	Total Current Assets

Cash And Short Term Investments	- 0.98	Net Debt
Net Debt	- 0.98	Total Current Assets
Net Debt	- 0.98	Cash
Net Debt	- 0.98	Total Assets
Common Stock	- 0.95	Retained Earnings
Total Liab	- 0.95	Retained Earnings